Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

The molecular and cellular basis of corticosteroid resistance.

Chikanza IC, Kozaci D, Chernajovsky Y.

J Endocrinol. 2003 Dec;179(3):301-10. Review.

2.
3.

The differential expression of corticosteroid receptor isoforms in corticosteroid-resistant and -sensitive patients with rheumatoid arthritis.

Kozaci DL, Chernajovsky Y, Chikanza IC.

Rheumatology (Oxford). 2007 Apr;46(4):579-85. Epub 2006 Oct 13.

5.

Corticosteroids: the drugs to beat.

Barnes PJ.

Eur J Pharmacol. 2006 Mar 8;533(1-3):2-14. Epub 2006 Jan 24. Review.

PMID:
16436275
6.
7.

Interleukin (IL)-23 p19 expression induced by IL-1beta in human fibroblast-like synoviocytes with rheumatoid arthritis via active nuclear factor-kappaB and AP-1 dependent pathway.

Liu FL, Chen CH, Chu SJ, Chen JH, Lai JH, Sytwu HK, Chang DM.

Rheumatology (Oxford). 2007 Aug;46(8):1266-73. Epub 2007 Jun 14.

8.

Kinin B1 and B2 receptor expression in osteoblasts and fibroblasts is enhanced by interleukin-1 and tumour necrosis factor-alpha. Effects dependent on activation of NF-kappaB and MAP kinases.

Brechter AB, Persson E, Lundgren I, Lerner UH.

Bone. 2008 Jul;43(1):72-83. doi: 10.1016/j.bone.2008.02.003. Epub 2008 Mar 10.

PMID:
18467203
12.

Avermectin exerts anti-inflammatory effect by downregulating the nuclear transcription factor kappa-B and mitogen-activated protein kinase activation pathway.

Ci X, Li H, Yu Q, Zhang X, Yu L, Chen N, Song Y, Deng X.

Fundam Clin Pharmacol. 2009 Aug;23(4):449-55. doi: 10.1111/j.1472-8206.2009.00684.x. Epub 2009 May 6.

PMID:
19453757
13.

Effects of the active metabolite of leflunomide, A77 1726, on cytokine release and the MAPK signalling pathway in human rheumatoid arthritis synoviocytes.

Vergne-Salle P, Léger DY, Bertin P, Trèves R, Beneytout JL, Liagre B.

Cytokine. 2005 Sep 7;31(5):335-48.

PMID:
16099671
14.

Diarctigenin, a lignan constituent from Arctium lappa, down-regulated zymosan-induced transcription of inflammatory genes through suppression of DNA binding ability of nuclear factor-kappaB in macrophages.

Kim BH, Hong SS, Kwon SW, Lee HY, Sung H, Lee IJ, Hwang BY, Song S, Lee CK, Chung D, Ahn B, Nam SY, Han SB, Kim Y.

J Pharmacol Exp Ther. 2008 Nov;327(2):393-401. doi: 10.1124/jpet.108.140145. Epub 2008 Aug 11.

16.

A selective small molecule IkappaB Kinase beta inhibitor blocks nuclear factor kappaB-mediated inflammatory responses in human fibroblast-like synoviocytes, chondrocytes, and mast cells.

Wen D, Nong Y, Morgan JG, Gangurde P, Bielecki A, Dasilva J, Keaveney M, Cheng H, Fraser C, Schopf L, Hepperle M, Harriman G, Jaffee BD, Ocain TD, Xu Y.

J Pharmacol Exp Ther. 2006 Jun;317(3):989-1001. Epub 2006 Mar 8.

17.
18.

Cordycepin inhibits IL-1beta-induced MMP-1 and MMP-3 expression in rheumatoid arthritis synovial fibroblasts.

Noh EM, Kim JS, Hur H, Park BH, Song EK, Han MK, Kwon KB, Yoo WH, Shim IK, Lee SJ, Youn HJ, Lee YR.

Rheumatology (Oxford). 2009 Jan;48(1):45-8. doi: 10.1093/rheumatology/ken417.

19.

Repression of inflammatory gene expression in human pulmonary epithelial cells by small-molecule IkappaB kinase inhibitors.

Newton R, Holden NS, Catley MC, Oyelusi W, Leigh R, Proud D, Barnes PJ.

J Pharmacol Exp Ther. 2007 May;321(2):734-42. Epub 2007 Feb 22.

20.

Suppressor of cytokine signalling (SOCS)-3 protects beta cells against IL-1beta-mediated toxicity through inhibition of multiple nuclear factor-kappaB-regulated proapoptotic pathways.

Karlsen AE, Heding PE, Frobøse H, Rønn SG, Kruhøffer M, Orntoft TF, Darville M, Eizirik DL, Pociot F, Nerup J, Mandrup-Poulsen T, Billestrup N.

Diabetologia. 2004 Nov;47(11):1998-2011. Epub 2004 Dec 2.

PMID:
15578154
Items per page

Supplemental Content

Write to the Help Desk